Simon Patterson Joins GoodRx Board of Directors

Former Dell Technologies and Skype Board member brings decades of tech, strategy and management experience

to GoodRx

SANTA MONICA, Calif. – May 30, 2024 – GoodRx (Nasdaq: GDRX), the leading destination for prescription savings

in the U.S., today announced the election of Simon Patterson to its Board of Directors. Currently leading EMEA

operations for the technology investment firm Silver Lake, Mr. Patterson brings to GoodRx decades of technology,

strategy and management experience. Mr. Patterson also serves on the boards of IVC Evidensia, New Zealand

Rugby Commercial, RAC, and ZPG, and previously served on the boards of Cegid, Dell Technologies, FlixBus,

Gerson Lehrman Group, Intelsat, MultiPlan and Skype.

“We believe Mr. Patterson’s significant expertise in finance and management, formed by his extensive experience

operating, advising and investing in high-growth technology companies, will be a strong asset to GoodRx,” said

Trevor Bezdek, GoodRx co-founder and Chairman of the Board. “We look forward to benefiting from his business

acumen as we scale our business to make prescription medications more accessible and affordable for all

Americans.”

Mr. Patterson has also joined the Board’s Nominating and Corporate Governance Committee.

About GoodRx

GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent

and lower prices for generic and brand medications, as well as comprehensive healthcare research and information.

We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011,

GoodRx has helped consumers save nearly $75 billion and is one of the most downloaded medical apps over the

past decade.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://

investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for

complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are

encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press

releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and

webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by

reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform

Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be

considered forward-looking statements, including without limitation statements regarding the scaling of our business,

benefits to consumers from our offerings and anticipated contributions from Simon Patterson in his directorship.

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and

other important factors that may cause our actual results, performance or achievements to be materially different from

any future results, performance or achievements expressed or implied by the forward-looking statements, including,

but not limited to, risks relating to our ability to attract and retain talent and the important factors discussed under the

caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2023, and our

other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the

forward-looking statements made in this press release. Any such forward-looking statements represent

management’s estimates as of the date of this press release. While we may elect to update such forward-looking

statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our

views to change.

Exhibit 99.1